Cargando…
PB2089: ALGORITHM FOR SEVERE COVID-19 RISK STRATIFICATION DEPENDING MONOCLONAL ANTI-CD20 ANTIBODIES TREATMENT DURATION IN NON-HODGKIN LYMPHOMA PATIENTS.
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431539/ http://dx.doi.org/10.1097/01.HS9.0000851188.53364.fc |
| _version_ | 1784780083151503360 |
|---|---|
| author | Sychevskaya, K. Kravchenko, S. Babaeva, F. Misyurina, A. Korneeva, A. Abdulpatahov, A. Abdurashidova, R. Keniaykina, A. Sarakaeva, Z. Fastova, E. Gorenkova, L. Nesterova, E. Mangasarova, Y. Bagova, M. Margolin, O. Magomedova, A. |
| author_facet | Sychevskaya, K. Kravchenko, S. Babaeva, F. Misyurina, A. Korneeva, A. Abdulpatahov, A. Abdurashidova, R. Keniaykina, A. Sarakaeva, Z. Fastova, E. Gorenkova, L. Nesterova, E. Mangasarova, Y. Bagova, M. Margolin, O. Magomedova, A. |
| author_sort | Sychevskaya, K. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9431539 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94315392022-08-31 PB2089: ALGORITHM FOR SEVERE COVID-19 RISK STRATIFICATION DEPENDING MONOCLONAL ANTI-CD20 ANTIBODIES TREATMENT DURATION IN NON-HODGKIN LYMPHOMA PATIENTS. Sychevskaya, K. Kravchenko, S. Babaeva, F. Misyurina, A. Korneeva, A. Abdulpatahov, A. Abdurashidova, R. Keniaykina, A. Sarakaeva, Z. Fastova, E. Gorenkova, L. Nesterova, E. Mangasarova, Y. Bagova, M. Margolin, O. Magomedova, A. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9431539/ http://dx.doi.org/10.1097/01.HS9.0000851188.53364.fc Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Sychevskaya, K. Kravchenko, S. Babaeva, F. Misyurina, A. Korneeva, A. Abdulpatahov, A. Abdurashidova, R. Keniaykina, A. Sarakaeva, Z. Fastova, E. Gorenkova, L. Nesterova, E. Mangasarova, Y. Bagova, M. Margolin, O. Magomedova, A. PB2089: ALGORITHM FOR SEVERE COVID-19 RISK STRATIFICATION DEPENDING MONOCLONAL ANTI-CD20 ANTIBODIES TREATMENT DURATION IN NON-HODGKIN LYMPHOMA PATIENTS. |
| title | PB2089: ALGORITHM FOR SEVERE COVID-19 RISK STRATIFICATION DEPENDING MONOCLONAL ANTI-CD20 ANTIBODIES TREATMENT DURATION IN NON-HODGKIN LYMPHOMA PATIENTS. |
| title_full | PB2089: ALGORITHM FOR SEVERE COVID-19 RISK STRATIFICATION DEPENDING MONOCLONAL ANTI-CD20 ANTIBODIES TREATMENT DURATION IN NON-HODGKIN LYMPHOMA PATIENTS. |
| title_fullStr | PB2089: ALGORITHM FOR SEVERE COVID-19 RISK STRATIFICATION DEPENDING MONOCLONAL ANTI-CD20 ANTIBODIES TREATMENT DURATION IN NON-HODGKIN LYMPHOMA PATIENTS. |
| title_full_unstemmed | PB2089: ALGORITHM FOR SEVERE COVID-19 RISK STRATIFICATION DEPENDING MONOCLONAL ANTI-CD20 ANTIBODIES TREATMENT DURATION IN NON-HODGKIN LYMPHOMA PATIENTS. |
| title_short | PB2089: ALGORITHM FOR SEVERE COVID-19 RISK STRATIFICATION DEPENDING MONOCLONAL ANTI-CD20 ANTIBODIES TREATMENT DURATION IN NON-HODGKIN LYMPHOMA PATIENTS. |
| title_sort | pb2089: algorithm for severe covid-19 risk stratification depending monoclonal anti-cd20 antibodies treatment duration in non-hodgkin lymphoma patients. |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431539/ http://dx.doi.org/10.1097/01.HS9.0000851188.53364.fc |
| work_keys_str_mv | AT sychevskayak pb2089algorithmforseverecovid19riskstratificationdependingmonoclonalanticd20antibodiestreatmentdurationinnonhodgkinlymphomapatients AT kravchenkos pb2089algorithmforseverecovid19riskstratificationdependingmonoclonalanticd20antibodiestreatmentdurationinnonhodgkinlymphomapatients AT babaevaf pb2089algorithmforseverecovid19riskstratificationdependingmonoclonalanticd20antibodiestreatmentdurationinnonhodgkinlymphomapatients AT misyurinaa pb2089algorithmforseverecovid19riskstratificationdependingmonoclonalanticd20antibodiestreatmentdurationinnonhodgkinlymphomapatients AT korneevaa pb2089algorithmforseverecovid19riskstratificationdependingmonoclonalanticd20antibodiestreatmentdurationinnonhodgkinlymphomapatients AT abdulpatahova pb2089algorithmforseverecovid19riskstratificationdependingmonoclonalanticd20antibodiestreatmentdurationinnonhodgkinlymphomapatients AT abdurashidovar pb2089algorithmforseverecovid19riskstratificationdependingmonoclonalanticd20antibodiestreatmentdurationinnonhodgkinlymphomapatients AT keniaykinaa pb2089algorithmforseverecovid19riskstratificationdependingmonoclonalanticd20antibodiestreatmentdurationinnonhodgkinlymphomapatients AT sarakaevaz pb2089algorithmforseverecovid19riskstratificationdependingmonoclonalanticd20antibodiestreatmentdurationinnonhodgkinlymphomapatients AT fastovae pb2089algorithmforseverecovid19riskstratificationdependingmonoclonalanticd20antibodiestreatmentdurationinnonhodgkinlymphomapatients AT gorenkoval pb2089algorithmforseverecovid19riskstratificationdependingmonoclonalanticd20antibodiestreatmentdurationinnonhodgkinlymphomapatients AT nesterovae pb2089algorithmforseverecovid19riskstratificationdependingmonoclonalanticd20antibodiestreatmentdurationinnonhodgkinlymphomapatients AT mangasarovay pb2089algorithmforseverecovid19riskstratificationdependingmonoclonalanticd20antibodiestreatmentdurationinnonhodgkinlymphomapatients AT bagovam pb2089algorithmforseverecovid19riskstratificationdependingmonoclonalanticd20antibodiestreatmentdurationinnonhodgkinlymphomapatients AT margolino pb2089algorithmforseverecovid19riskstratificationdependingmonoclonalanticd20antibodiestreatmentdurationinnonhodgkinlymphomapatients AT magomedovaa pb2089algorithmforseverecovid19riskstratificationdependingmonoclonalanticd20antibodiestreatmentdurationinnonhodgkinlymphomapatients |